BGLC
BioNexus Gene Lab Corp Common stock
NASDAQ: BGLC · BASIC MATERIALS · SPECIALTY CHEMICALS
$2.09
+1.46% today
Updated 2026-04-30
Market cap
$5.37M
P/E ratio
—
P/S ratio
0.72x
EPS (TTM)
$-1.61
Dividend yield
—
52W range
$2 – $16
Volume
0.0M
BioNexus Gene Lab Corp Common stock (BGLC) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-835.00 | $357216.00 | $-274080.00 | $-217273.00 | $552680.00 | $9161.00 | $544028.00 | $-1.76M | $-2.23M | $-1.84M |
| Capital expenditures | $0.00 | $314821.00 | $39621.00 | $12817.00 | $421621.00 | $3162.00 | $54171.00 | $149397.00 | $226989.00 | $36971.00 |
| Depreciation | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | — | — | — | — | — | — | $0.00 | $511740.00 | $141000.00 | $794770.00 |
| Free cash flow | $-835.00 | $42395.00 | $-313701.00 | $-230090.00 | $131059.00 | $5999.00 | $489857.00 | $-1.91M | $-2.46M | $-1.88M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | $6310.00 | $22036.00 | $0.00 | $115379.00 | $68130.00 | $22112.00 |
| Share repurchases | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | $1.93M | $-509635.00 | — | — | — | — |